Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
SEMA3F
REST API REST API
Homo sapiens
SEMA3F is differentially expressed in 301 experiments: 153 organism parts: liver, lung, ... (151 more);, 205 disease states: normal, breast carcinoma, ... (203 more);, 92 cell types 415 cell lines 41 compound treatments and 80 other conditions.
Synonyms Sema4, SEMAK
Orthologs Q8AXA8_CHICK (Gallus gallus)   Sema3f (Mus musculus)   sema3fb (Danio rerio)   sema3fa (Danio rerio)   SEMA3F (Bos taurus)   Sema3f (Rattus norvegicus)   sema3f (Xenopus laevis)   SEMA3F (Canis familiaris)   (Compare orthologs)
InterPro Term Ig_sub, Plexin-like, Ig-like, Ig_sub2, Semaphorin/CD100_Ag
Gene Ontology Term negative chemotaxis, protein binding, extracellular space, membrane, extracellular region, axon guidance, multicellular organismal development, receptor activity, neural crest cell migration, chemorepellent activity, negative regulation of axon extension involved in axon guidance
UniProt Accession Q13275, C9J1V2, C9J4H5, C9IYS6, C9JPG5, C9JQ85
Search EB-eye ENSG00000001617
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, E-GEOD-1577, ... (30 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, ... (48 experiments)

Factor Value U/D Experiments
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
HT1080
2
E-GEOD-20089, E-MTAB-37
KG1
2
E-GEOD-24147, E-MTAB-37
LNCaP
2
E-GEOD-14990, E-GEOD-14464
MDAMB175VII
2
E-MTAB-37, E-MTAB-62
MOLT4
2
E-MTAB-62, E-MTAB-37
409 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-20193, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, ... (48 experiments)

Factor Value U/D Experiments
endothelial cell
1
3
E-GEOD-3920, E-GEOD-96, E-GEOD-19240, E-GEOD-3998
plasma cell
2
E-MEXP-2360, E-GEOD-6691
721 B lymphoblast
2
2
E-AFMX-5, E-TABM-145
Leukocytes
1
E-GEOD-21909
iPS cells from episomal vectors (Defined Factor)
1
E-GEOD-20033
iPS cells from episomal vectors (Defined Factor sub-clone)
1
E-GEOD-20033
86 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-GEOD-16363, ... (51 experiments)

Factor Value U/D Experiments
cervical carcinoma
3
E-MTAB-37, E-MTAB-62, E-GEOD-5823
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
lung adenocarcinoma
1
2
E-MTAB-37, E-MTAB-62, E-MEXP-231
mock infected
1
E-MEXP-1072
acute quadriplegic myopathy
1
E-MTAB-62
age-related macular degeneration
1
E-GEOD-1719
199 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-5741, E-GEOD-15205, E-GEOD-5542, E-GEOD-5824, ... (23 experiments)

Factor Value U/D Experiments
mannitol
1
E-GEOD-6400
vanadium pentoxide
1
E-GEOD-5339
5-aza-2'-deoxycytidine
3
1
E-MEXP-1269
placebo
1
E-MEXP-1335
unknown
1
E-GEOD-7307
-
1
1
E-MEXP-2645
35 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-20033, E-GEOD-4667, E-MEXP-2283, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-GEOD-2509, E-TABM-147, ... (7 experiments)

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-MTAB-108, ... (8 experiments)

Genotype
studied in E-GEOD-22056, E-GEOD-3494, E-GEOD-2466, E-GEOD-21750, E-TABM-321, ... (12 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-13073, E-MEXP-1220, E-GEOD-5681, E-TABM-127, ... (11 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-16194, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-1926, E-GEOD-3606, E-GEOD-16363, ... (33 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-9723, E-MEXP-561 ... (5 experiments)

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Localisation of metastases
studied in E-GEOD-22541

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-1309, E-GEOD-21750, E-GEOD-1657

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-22097, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-1422, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-MEXP-548, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-18995

Sex
studied in E-GEOD-2466, E-GEOD-22541, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Tissue
studied in E-GEOD-30573

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19136

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-89, E-GEOD-4290, E-GEOD-4271, E-GEOD-22541, E-GEOD-1561, ... (7 experiments)

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.395 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM